Previous close | 0.7000 |
Open | 0.7000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 5.00 |
Expiry date | 2025-02-21 |
Day's range | 0.7000 - 0.7000 |
Contract range | N/A |
Volume | |
Open interest | N/A |
The accounting accusations in a report by Gotham City Research last January sparked a slump in the Grifols share price. Grifols has denied the accusations and also filed a lawsuit in the United States against the fund and its founder. Srinivasan will start on Sept. 16, succeeding Alfredo Arroyo, who is retiring after 17 years at the company, Grifols said in Thursday's filing to the Spanish stock market regulator.
Scranton Enterprises, an entity tied to the Grifols family, said on Tuesday it has reached an agreement with a private investor to refinance 377 million euros ($404.5 million) in debt of one of its units. Spanish drugmaker Grifols' market value has shed billions of euros since short-sheller Gotham City Research released a report in early January accusing the company of overstating earnings and understating debt. Grifols has repeatedly denied the claims.
Biotest, a Grifols Group company, is expected to launch its recently FDA-approved intravenous immunoglobulin in the U.S. in first quarter 2025 Yimmugo will be distributed by Kedrion in the U.S. as part of a broader Group channel strategy, with Grifols focusing on continued growth of its current portfolio for this market It adds to Grifols’ strong franchise of intravenous and subcutaneous immunoglobulins to meet growing patient demand for these therapeutics Yimmugo will be followed by other prote